Clinical Trial Update: Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants [Phase 4]

View source ↗

Summary

Phase 4 trial updating safety and reactogenicity of DTPa-IPV/Hib vaccine administered at 3, 4, 5 and 18 months in healthy infants; completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acellular Pertussis
• Diphtheria
• Haemophilus Influenzae Type
• Poliomyelitis
• Tetanus

Drugs mentioned

• DTPa-IPV/Hib (Diphtheria and tetanus toxoids and acellular pertussis vaccine; Inactivated poliovirus vaccine; Haemophilus influenzae type b conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diphtheria, Tetanus | Phase 4 | Status: COMPLETED | Results posted: 2017-02-07